• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers win $1.8m NIH grant to develop implantable system for HIV prevention

March 27, 2017 By Sarah Faulkner

Researchers win $1.8m NIH grant to develop implantable system for HIV preventionResearchers at the University of North Carolina at Chapel Hill won a $1.8 million grant from the National Institutes of Health to develop an implantable drug delivery system for sustained HIV-prevention. The team said it plans to develop an injectable system that steadily releases pre-exposure prophylaxis over long periods of time.

The injectable compound is composed of PrEP, a polymer and a solvent, according to the researchers. Once injected under the skin, the liquid solidifies into an implant that releases drug as the polymer slowly degrades.

The team said it plans to evaluate the efficacy of its formulation using pre-clinical models from UNC.

“This long-acting injectable formulation could provide a discrete and efficient method to protect against HIV infection and improve adherence, which is one of the major challenges of oral pre-exposure prophylaxis, or PrEP,” co-principal investigator Rahima Benhabbour said in prepared remarks. “The formulation is adaptable to a number of drugs alone or in combination and can be fine tuned to meet a targeted release regimen.”

“The goal of our study is to develop an injectable polymer-based delivery system for long-acting PrEP that offers durable, sustained protection from HIV transmission, high efficacy of HIV inhibition, increased adherence and the ability to be removed in case of an unanticipated adverse event or when considering discontinuation of this form of PrEP,” co-principal investigator Martina Kovarova added. “If discontinuation of treatment is desired, the implant would be readily removable.”

The team said the Centers for Disease Control and Prevention will facilitate further testing of the injectable implant in animal models.

“We are excited to be part of the team that is undertaking this important study for HIV prevention,” CDC microbiologist Gerardo Garci-Lerma said.

Ultimately, the researchers aim to produce an injectable implant that will provide 3 months of HIV prevention to patients.

“We’re in the very beginning stages of this project,” Kovarova said. “This novel formulation has outstanding properties, and we are excited to move ahead.”

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Implants, Research & Development Tagged With: University of North Carolina at Chapel Hill

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS